9 research outputs found
European Lung Cancer Working Party Clinical Practice Guidelines. Small Cell Lung Cnacer: IV. Limited disease
The present guidelines on the management of limited disease small cell lung cancer (SCLC) were formulated by the ELCWP in April 2007. They are designed to answer the following seven questions: 1) What is the definition of limited disease? 2) Should chest radiotherapy be provided and what are the benefits? 3) What is the optimal timing and mode of administration of chest irradiation? 4) Which are the optimal radiotherapy parameters: dose, fractionation, target volume? 5) What is the optimal chemotherapy regimen for limited disease SCLC? 6) Should prophylactic cranial irradiation be provided, when and for which patients? 7) What is the additional role of thoracic surgery in early SCLC
Traitement du cancer bronchique à petites cellules: Maladies limitées. Les recommandations de pratique clinique de l'European Lung Cancer Working Party
SCOPUS: ar.jinfo:eu-repo/semantics/publishe
European Lung Cancer Working Party Clinical Practice Guidelines. Small cell lung cancer: IV. Limited disease.
info:eu-repo/semantics/publishe
Traitement du cancer bronchique à petites cellules: Maladies étendues. Les recommandations de pratique clinique de l'European Lung Cancer Working Party
SCOPUS: re.jinfo:eu-repo/semantics/publishe
European Lung Cancer Working Party Clinical Practice Guidelines. Small cell lung cancer: V. Extensive diseases.
info:eu-repo/semantics/publishe
Traitement des cancers bronchiques non à petites cellules: Maladies avancées (métastatiques). Les recommandations de pratique clinique de l'European Lung Cancer Working Party
SCOPUS: re.jinfo:eu-repo/semantics/publishe
A three-arm phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancer
SCOPUS: ar.jinfo:eu-repo/semantics/publishe
A Phase III randomized study comparing a chemotherapy with cisplatin and etoposide to a etoposide regimen without cisplatin for patients with extensive small-cell lung cancer
Introduction: In a literature meta-analysis, we showed survival benefits for regimens including cisplatin [hazard ratio (HR) 0.61; 95% confidence interval (CI), 0.57-0.66] and for those including etoposide (HR 0.65; 0.61-0.69). That benefit was mainly observed when etoposide alone or in combination with cisplatin was included in the chemotherapy regimens. Our objective was to determine if chemotherapy with both drugs improves survival in comparison to a non-platinum regimen with etoposide. Methods: Extensive small-cell lung cancer patients were randomized between cisplatin-etoposide (CE) and ifosfamide + etoposide + epirubicin regimen (IVE) between 2000 and 2013. Results: 176 and 170 eligible patients were allocated to CE and IVE (315 deaths were required before analysis), respectively. Objective response rates were not significantly different: 60% with CE and 59% with IVE. No statistically significant difference in median survival and 1-year and 2-year was observed with rates of 9.6 months, 31 and 5% for CE and 10 months, 39 and 9% for IVE, respectively. HR was 0.84 (95% CI 0.68-1.05, p = 0.16). Only two prognostic factors for survival were retained in multivariate analysis: sex with HR = 0.69 (95% CI 0.49-0.97, p = 0.03) and performance status with HR = 0.53 (95% CI 0.49-0.97, p < 0.0001). After adjustment for these prognostic factors, HR for survival was 0.83 (95% CI 0.65-1.08, p = 0.17). There was more thrombopenia in the CE regimen and more leukopenia with IVE. Conclusion: Combination of CE failed to improve survival in comparison to an etoposide-containing regimen without cisplatin. Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT00658580?term=ELCWP+01994&rank=1, identifier NCT00658580. © 2017 Berghmans, Scherpereel, Meert, Giner, Lecomte, Lafitte, Leclercq, Paesmans and Sculier